文献速递甲状腺与颈部外科

RET V804M突变甲状腺髓样癌:比预期更惰性?

Medullary thyroid cancer with RET V804M mutation: more indolent than expected?
PubMed 文献 · Surgery · 2022-09-21

单中心回顾性分析1996年至2020年79例RET V804M突变患者,其中68例接受手术。多数患者无经典MEN2A表现,47.1%病理为甲状腺髓样癌(中位肿瘤大小3.0 mm),术前降钙素>5 pg/mL与最终病理为甲状腺髓样癌相关(OR=13.3,95%CI 3.2-56.3,P<.001)。

要点

  • RET V804M突变患者多表现为惰性疾病,无嗜铬细胞瘤或甲旁亢。
  • 术前降钙素>5 pg/mL与甲状腺髓样癌病理显著相关。
  • 降钙素>5 pg/mL或可指导监测与手术时机。

核心结论

  • RET V804M突变手术患者多数为惰性疾病,缺乏经典MEN2A特征。
  • 术前降钙素>5 pg/mL与最终病理为甲状腺髓样癌独立相关。

研究设计与样本

  • 单中心回顾性队列研究,纳入1996年1月至2020年12月RET V804M突变患者79例。
  • 分析基线特征、手术细节、病理、生化及长期随访数据。

主要发现

  • 79例患者中无人发生嗜铬细胞瘤、甲旁亢或死亡。
  • 68例手术患者中,53例(77.9%)行全甲状腺切除,15例(22.1%)行全甲状腺切除加中央区淋巴结清扫伴或不伴侧颈淋巴结清扫。
  • 病理良性占27.9%,单纯甲状腺乳头状癌占1.5%,C细胞增生占23.5%,甲状腺髓样癌占47.1%(中位肿瘤大小3.0 mm)。
  • 术后3例降钙素升高,中位随访时间60.0个月。

关键数值与推荐

  • 术前降钙素>5 pg/mL与最终病理为甲状腺髓样癌相关(OR=13.3;95%CI 3.2-56.3;P<.001)。

临床怎么用

  • 对RET V804M突变患者,术前降钙素>5 pg/mL提示甲状腺髓样癌风险显著增加,可据此指导监测频率和手术时机。

局限性

  • 单中心回顾性研究,样本量有限,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Significant genotype-phenotype variability among multiple endocrine neoplasia type 2A patients with a RET V804M mutation has been reported. METHODS: Patients with a RET V804M mutation treated at a single center were identified (January 1996-December 2020). The baseline characteristics, operative details, pathology, biochemical, and long-term data were analyzed. RESULTS: There were 79 patients; none developed pheochromocytoma or hyperparathyroidism or died in the study period. The mean age was 41.5 years (range = 1.0-81.0 years); 46.8% were men. Of 68 surgical patients, 53 (77.9%) underwent total thyroidectomy and 15 (22.1%) underwent total thyroidectomy with central neck dissection with or without lateral neck dissection. Twenty-four patients had elevated preoperative calcitonin, of whom 12 underwent total thyroidectomy (median = 7.5; range = 5.0-237.0 pg/mL), 10 underwent total thyroidectomy + central neck dissection (median = 27.6; range = 5.1-147.0 pg/mL), and 2 underwent total thyroidectomy + central neck dissection + lateral neck dissection (median = 3182.0; range = 361.0-6003.0 pg/mL). Pathology was benign (27.9%), papillary thyroid cancer alone (1.5%), C-cell hyperplasia (23.5%), and medullary thyroid cancer (47.1%; median tumor size = 3.0 mm). Three patients had elevated calcitonin postoperatively (median follow-up time = 60.0 months). In adjusted modeling, a preoperative calcitonin >5 pg/mL was associated with having medullary thyroid cancer on final pathology (odds ratio = 13.3; 95% confidence interval, 3.2-56.3; P < .001). CONCLUSION: In this large United States cohort of surgical patients with a RET V804M mutation, most had indolent disease and were without classic multiple endocrine neoplasia type 2A features. Calcitonin >5 pg/mL may serve as a meaningful value to guide surveillance and timing of surgery.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Frisco NA, Gunn AH, Thomas SM, et al. Medullary thyroid cancer with RET V804M mutation: more indolent than expected? Surgery. 2022. PMID: 36150924. doi:10.1016/j.surg.2022.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。